Exelixis Inc Selling, General and Administrative Expense
Exelixis Inc (EXEL) reported Selling, General and Administrative Expense of $147.63 million for the 3-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- Exelixis Inc selling, general and administrative expense for the quarter ending 2026-07-03 was $147.63M, a 9.47% increase year-over-year.
- Exelixis Inc selling, general and administrative expense for the quarter ending 2026-04-03 was $139.60M, a 1.76% increase year-over-year.
- Exelixis Inc selling, general and administrative expense for the quarter ending 2026-01-02 was $123.02M, a 8.42% decline year-over-year.
- Exelixis Inc selling, general and administrative expense for the quarter ending 2025-10-03 was $123.66M, a 10.61% increase year-over-year.
- Exelixis Inc selling, general and administrative expense for fiscal 2026 was $518.73M, a 5.40% increase from fiscal 2025.
- Exelixis Inc selling, general and administrative expense for fiscal 2025 was $492.13M, a 9.32% decline from fiscal 2023.
- Exelixis Inc selling, general and administrative expense for fiscal 2023 was $542.71M, a 18.02% increase from fiscal 2022.
- Exelixis Inc selling, general and administrative expense for fiscal 2022 was $459.86M, a 14.47% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-07-03 | $147.63M 10-Q · filed 2026-08-05 | $287.23M 10-Q · filed 2026-08-05 | $410.26M derived: sum of 3 quarters · filed 2026-08-05 | $533.92M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-04-03 | $139.60M 10-Q · filed 2026-05-05 | $262.63M derived: sum of 2 quarters · filed 2026-05-05 | $386.29M derived: sum of 3 quarters · filed 2026-05-05 | $521.15M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-01-02 | $123.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $246.69M derived: sum of 2 quarters · filed 2026-02-10 | $381.54M derived: sum of 3 quarters · filed 2026-08-05 | $518.73M 10-K · filed 2026-02-10 | ||
| 2025-10-03 | $123.66M 10-Q · filed 2025-11-04 | $258.52M derived: sum of 2 quarters · filed 2026-08-05 | $395.70M 10-Q · filed 2025-11-04 | $530.03M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-07-04 | $134.86M 10-Q · filed 2026-08-05 | $272.04M 10-Q · filed 2026-08-05 | $406.37M derived: sum of 3 quarters · filed 2026-08-05 | $518.17M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-04-04 | $137.18M 10-Q · filed 2026-05-05 | $271.51M derived: sum of 2 quarters · filed 2026-05-05 | $383.31M derived: sum of 3 quarters · filed 2026-05-05 | $515.33M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2025-01-03 | $134.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $246.13M derived: sum of 2 quarters · filed 2026-02-10 | $378.14M derived: sum of 3 quarters · filed 2026-02-10 | $492.13M 10-K · filed 2026-02-10 | ||
| 2024-09-27 | $111.80M 10-Q · filed 2025-11-04 | $243.82M derived: sum of 2 quarters · filed 2025-11-04 | $357.80M 10-Q · filed 2025-11-04 | $489.24M derived: sum of 4 quarters · filed 2026-02-10 | ||
| 2024-06-28 | $132.01M 10-Q · filed 2025-07-28 | $246.00M 10-Q · filed 2025-07-28 | $377.44M derived: sum of 3 quarters · filed 2026-02-10 | $515.58M derived: sum of 4 quarters · filed 2026-02-10 | ||
| 2024-03-29 | $113.98M 10-Q · filed 2025-05-13 | $245.43M derived: sum of 2 quarters · filed 2026-02-10 | $383.57M derived: sum of 3 quarters · filed 2026-02-10 | $525.29M derived: sum of 4 quarters · filed 2026-02-10 | ||
| 2023-12-29 | $131.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $269.58M derived: sum of 2 quarters · filed 2026-02-10 | $411.31M derived: sum of 3 quarters · filed 2026-02-10 | $542.71M 10-K · filed 2026-02-10 | ||
| 2023-09-29 | $138.14M 10-Q · filed 2024-10-29 | $279.87M derived: sum of 2 quarters · filed 2024-10-29 | $411.26M 10-Q · filed 2024-10-29 | $530.51M derived: sum of 4 quarters · filed 2025-02-11 | ||
| 2023-06-30 | $141.72M 10-Q · filed 2024-08-06 | $273.12M 10-Q · filed 2024-08-06 | $392.37M derived: sum of 3 quarters · filed 2025-02-11 | $507.35M derived: sum of 4 quarters · filed 2025-02-11 | ||
| 2023-03-31 | $131.40M 10-Q · filed 2024-04-30 | $250.65M derived: sum of 2 quarters · filed 2025-02-11 | $365.63M derived: sum of 3 quarters · filed 2025-02-11 | $488.39M derived: sum of 4 quarters · filed 2025-02-11 | ||
| 2022-12-30 | $119.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $234.23M derived: sum of 2 quarters · filed 2025-02-11 | $356.99M derived: sum of 3 quarters · filed 2025-02-11 | $459.86M 10-K · filed 2025-02-11 | ||
| 2022-09-30 | $114.98M 10-Q · filed 2023-11-01 | $237.74M derived: sum of 2 quarters · filed 2023-11-01 | $340.61M 10-Q · filed 2023-11-01 | $439.92M derived: sum of 4 quarters · filed 2024-02-06 | ||
| 2022-07-01 | $122.76M 10-Q · filed 2023-08-01 | $225.62M 10-Q · filed 2023-08-01 | $324.93M derived: sum of 3 quarters · filed 2024-02-06 | $426.49M derived: sum of 4 quarters · filed 2024-02-06 | ||
| 2022-04-01 | $102.86M 10-Q · filed 2023-05-09 | $202.17M derived: sum of 2 quarters · filed 2024-02-06 | $303.73M derived: sum of 3 quarters · filed 2024-02-06 | $402.23M derived: sum of 4 quarters · filed 2024-02-06 | ||
| 2021-12-31 | $99.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $200.87M derived: sum of 2 quarters · filed 2024-02-06 | $299.36M derived: sum of 3 quarters · filed 2024-02-06 | $401.71M 10-K · filed 2024-02-06 | ||
| 2021-10-01 | $101.56M 10-Q · filed 2022-11-01 | $200.05M derived: sum of 2 quarters · filed 2022-11-01 | $302.40M 10-Q · filed 2022-11-01 | $384.84M derived: sum of 4 quarters · filed 2023-02-07 | ||
| 2021-07-02 | $98.50M 10-Q · filed 2022-08-09 | $200.85M 10-Q · filed 2022-08-09 | $283.29M derived: sum of 3 quarters · filed 2023-02-07 | $371.47M derived: sum of 4 quarters · filed 2023-02-07 | ||
| 2021-04-02 | $102.35M 10-Q · filed 2022-05-10 | $184.79M derived: sum of 2 quarters · filed 2023-02-07 | $272.98M derived: sum of 3 quarters · filed 2023-02-07 | $332.77M derived: sum of 4 quarters · filed 2023-02-07 | ||
| 2021-01-01 | $82.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $170.62M derived: sum of 2 quarters · filed 2023-02-07 | $230.41M derived: sum of 3 quarters · filed 2023-02-07 | $293.36M 10-K · filed 2023-02-07 | ||
| 2020-10-02 | $88.19M 10-Q · filed 2021-11-02 | $147.98M derived: sum of 2 quarters · filed 2021-11-02 | $210.92M 10-Q · filed 2021-11-02 | $268.94M derived: sum of 4 quarters · filed 2022-02-18 | ||
| 2020-07-03 | $59.79M 10-Q · filed 2021-08-05 | $122.73M 10-Q · filed 2021-08-05 | $180.76M derived: sum of 3 quarters · filed 2022-02-18 | $232.02M derived: sum of 4 quarters · filed 2022-02-18 | ||
| 2020-04-03 | $62.94M 10-Q · filed 2021-05-06 | $120.97M derived: sum of 2 quarters · filed 2022-02-18 | $172.23M derived: sum of 3 quarters · filed 2022-02-18 | $231.05M derived: sum of 4 quarters · filed 2022-02-18 | ||
| 2020-01-03 | $58.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $109.29M derived: sum of 2 quarters · filed 2022-02-18 | $168.11M derived: sum of 3 quarters · filed 2022-02-18 | $228.24M 10-K · filed 2022-02-18 | ||
| 2019-09-27 | $51.27M 10-Q · filed 2020-11-05 | $110.08M derived: sum of 2 quarters · filed 2020-11-05 | $170.22M 10-Q · filed 2020-11-05 | $222.59M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-06-28 | $58.81M 10-Q · filed 2020-08-06 | $118.95M 10-Q · filed 2020-08-06 | $171.33M derived: sum of 3 quarters · filed 2020-08-06 | $219.45M derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-29 | $60.14M 10-Q · filed 2020-05-05 | $112.52M derived: sum of 2 quarters · filed 2020-05-05 | $160.63M derived: sum of 3 quarters · filed 2020-05-05 | $212.49M derived: sum of 4 quarters · filed 2020-05-05 | ||
| 2018-12-28 | $52.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $100.50M derived: sum of 2 quarters · filed 2020-02-25 | $152.35M derived: sum of 3 quarters · filed 2020-02-25 | $206.37M 10-K · filed 2021-02-11 | ||
| 2018-09-28 | $48.12M 10-Q · filed 2019-10-30 | $99.97M derived: sum of 2 quarters · filed 2019-10-30 | $153.99M 10-Q · filed 2019-10-30 | $200.24M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-29 | $51.85M 10-Q · filed 2019-07-31 | $105.87M 10-Q · filed 2019-07-31 | $152.12M derived: sum of 3 quarters · filed 2020-02-25 | $190.24M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-30 | $54.02M 10-Q · filed 2019-05-01 | $52.64M 10-Q · filed 2018-05-02 | $100.26M derived: sum of 2 quarters · filed 2020-02-25 | $138.39M derived: sum of 3 quarters · filed 2020-02-25 | ||
| 2017-12-29 | $46.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $84.38M derived: sum of 2 quarters · filed 2020-02-25 | $159.33M 10-K · filed 2020-02-25 | $159.36M 10-K · filed 2018-02-26 | ||
| 2017-09-30 | $38.13M 10-Q · filed 2017-11-01 | $113.12M 10-Q · filed 2017-11-01 | ||||
| 2017-09-29 | $38.13M 10-Q · filed 2018-11-01 | $78.80M derived: sum of 2 quarters · filed 2018-11-01 | $113.08M 10-Q · filed 2018-11-01 | $126.09M derived: sum of 4 quarters · filed 2018-11-01 | ||
| 2017-06-30 | $40.67M 10-Q · filed 2018-08-01 | $40.73M 10-Q · filed 2017-08-02 | $74.99M 10-Q · filed 2017-08-02 | $87.96M derived: sum of 3 quarters · filed 2018-08-01 | $120.42M derived: sum of 4 quarters · filed 2018-08-01 | |
| 2017-03-31 | $34.26M 10-Q · filed 2017-05-01 | $47.29M derived: sum of 2 quarters · filed 2018-05-02 | $79.75M derived: sum of 3 quarters · filed 2018-05-02 | $115.58M derived: sum of 4 quarters · filed 2018-05-02 | ||
| 2016-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $45.47M derived: sum of 2 quarters · filed 2017-11-01 | $81.29M derived: sum of 3 quarters · filed 2017-11-01 | $116.14M 10-K · filed 2017-02-27 | ||
| 2016-12-30 | $116.14M 10-K · filed 2019-02-22 | |||||
| 2016-09-30 | $32.46M 10-Q · filed 2017-11-01 | $68.29M derived: sum of 2 quarters · filed 2017-11-01 | $103.14M 10-Q · filed 2017-11-01 | $120.29M derived: sum of 4 quarters · filed 2017-11-01 | ||
| 2016-06-30 | $35.82M 10-Q · filed 2017-08-02 | $70.68M 10-Q · filed 2017-08-02 | $87.82M derived: sum of 3 quarters · filed 2017-08-02 | $105.67M derived: sum of 4 quarters · filed 2017-08-02 | ||
| 2016-03-31 | $34.86M 10-Q · filed 2017-05-01 | $52.00M derived: sum of 2 quarters · filed 2017-05-01 | $69.84M derived: sum of 3 quarters · filed 2017-05-01 | $82.63M derived: sum of 4 quarters · filed 2017-05-01 | ||
| 2016-01-01 | $57.30M 10-K · filed 2018-02-26 | |||||
| 2015-12-31 | $17.14M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $34.98M derived: sum of 2 quarters · filed 2017-02-27 | $47.77M derived: sum of 3 quarters · filed 2017-02-27 | $57.30M 10-K · filed 2017-02-27 | ||
| 2015-09-30 | $17.84M 10-Q · filed 2016-11-03 | $30.63M derived: sum of 2 quarters · filed 2016-11-03 | $40.16M 10-Q · filed 2016-11-03 | $49.93M derived: sum of 4 quarters · filed 2017-02-27 | ||
| 2015-06-30 | $12.79M 10-Q · filed 2016-08-03 | $22.32M 10-Q · filed 2016-08-03 | $32.09M derived: sum of 3 quarters · filed 2017-02-27 | $41.99M derived: sum of 4 quarters · filed 2017-02-27 | ||
| 2015-03-31 | $9.53M 10-Q · filed 2016-05-04 | $19.30M derived: sum of 2 quarters · filed 2017-02-27 | $29.20M derived: sum of 3 quarters · filed 2017-02-27 | $45.67M derived: sum of 4 quarters · filed 2017-02-27 | ||
| 2014-12-31 | $9.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $19.67M derived: sum of 2 quarters · filed 2017-02-27 | $36.14M derived: sum of 3 quarters · filed 2017-02-27 | $50.83M 10-K · filed 2017-02-27 | ||
| 2014-09-30 | $9.91M 10-Q · filed 2015-11-10 | $26.37M derived: sum of 2 quarters · filed 2015-11-10 | $41.06M 10-Q · filed 2015-11-10 | $54.70M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-06-30 | $16.47M 10-Q · filed 2015-08-11 | $31.16M 10-Q · filed 2015-08-11 | $44.79M derived: sum of 3 quarters · filed 2016-02-29 | $58.39M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-03-31 | $14.69M 10-Q · filed 2015-04-30 | $28.33M derived: sum of 2 quarters · filed 2016-02-29 | $41.92M derived: sum of 3 quarters · filed 2016-02-29 | $55.10M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | $13.63M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $27.23M derived: sum of 2 quarters · filed 2016-02-29 | $40.41M derived: sum of 3 quarters · filed 2016-02-29 | $50.96M 10-K · filed 2016-02-29 | ||
| 2013-09-30 | $13.60M 10-Q · filed 2014-11-04 | $26.78M derived: sum of 2 quarters · filed 2014-11-04 | $37.32M 10-Q · filed 2014-11-04 | $47.15M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | $13.18M 10-Q · filed 2014-07-31 | $23.73M 10-Q · filed 2014-07-31 | $33.55M derived: sum of 3 quarters · filed 2015-03-02 | $40.90M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | $10.54M 10-Q · filed 2014-05-01 | $20.37M derived: sum of 2 quarters · filed 2015-03-02 | $27.72M derived: sum of 3 quarters · filed 2015-03-02 | |||
| 2012-12-31 | $9.83M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $17.17M derived: sum of 2 quarters · filed 2015-03-02 | $31.84M 10-K · filed 2015-03-02 | |||
| 2012-09-30 | $7.34M 10-Q · filed 2013-10-30 | $22.01M 10-Q · filed 2013-10-30 | ||||
| 2011-12-31 | $33.13M 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |